Recruiting PHASE4 INTERVENTIONAL 1-arm
NCT07124351
Intraoperative Imaging of Gastrointestinal Malignancies Using Pafolacianine (CYTALUX™)
Sponsor: Cedars-Sinai Medical Center
Interventions
CYTALUX™ (pafolacianine)
Updated 2 times since 2025 Last updated: Sep 9, 2025 Started: Sep 5, 2025 Primary completion: Aug 31, 2026 Completion: Sep 30, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
Listed as NCT07124351, this PHASE4 trial focuses on Appendiceal Cancer and Esophageal Cancer and remains actively recruiting participants. Sponsored by Cedars-Sinai Medical Center, it has been updated 2 times since 2025, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
2 versions recorded-
Oct 2025 — Present [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting · Phase: PHASE1 → PHASE4
-
Sep 2025 — Oct 2025 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Cedars-Sinai Medical Center
- On Target Laboratories, LLC
Data source: Cedars-Sinai Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .